[go: up one dir, main page]

NO20012961L - Trisykliske farnesylproteintransferase-inhibitorer - Google Patents

Trisykliske farnesylproteintransferase-inhibitorer

Info

Publication number
NO20012961L
NO20012961L NO20012961A NO20012961A NO20012961L NO 20012961 L NO20012961 L NO 20012961L NO 20012961 A NO20012961 A NO 20012961A NO 20012961 A NO20012961 A NO 20012961A NO 20012961 L NO20012961 L NO 20012961L
Authority
NO
Norway
Prior art keywords
group
protein transferase
farnesyl protein
stands
transferase inhibitors
Prior art date
Application number
NO20012961A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012961D0 (no
Inventor
Arthur G Taveras
Ronald J Doll
Alan Bruce Cooper
Johan A Ferreira
Timothy Guzi
Alan K Mallams
Dinanath F Rane
Viyyoor Moopil Girijavallabhan
Adriano Afonso
Cynthia J Aki
Jianping Chao
Carmen Alvarez
Joseph M Kelly
Tarik Lalwani
Jagdish A Desai
James J S Wang
Jay Weinstein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20012961D0 publication Critical patent/NO20012961D0/no
Publication of NO20012961L publication Critical patent/NO20012961L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012961A 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer NO20012961L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
PCT/US1999/027939 WO2000037459A1 (fr) 1998-12-18 1999-12-16 Inhibiteurs de la farnesyl proteine transferase tryciclique

Publications (2)

Publication Number Publication Date
NO20012961D0 NO20012961D0 (no) 2001-06-15
NO20012961L true NO20012961L (no) 2001-08-16

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012961A NO20012961L (no) 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer

Country Status (20)

Country Link
EP (1) EP1140902A1 (fr)
JP (1) JP2002533336A (fr)
KR (1) KR20010081116A (fr)
CN (1) CN1326850C (fr)
AR (1) AR021718A1 (fr)
AU (1) AU776558B2 (fr)
BR (1) BR9916314A (fr)
CA (1) CA2354779A1 (fr)
CO (1) CO5160350A1 (fr)
CZ (1) CZ20011950A3 (fr)
HU (1) HUP0202152A2 (fr)
IL (1) IL143408A0 (fr)
NO (1) NO20012961L (fr)
NZ (1) NZ511878A (fr)
PE (1) PE20001342A1 (fr)
PL (1) PL348293A1 (fr)
SK (1) SK7592001A3 (fr)
TR (1) TR200101755T2 (fr)
WO (1) WO2000037459A1 (fr)
ZA (1) ZA200104233B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK7592001A3 (en) 1998-12-18 2002-03-05 Schering Corp Tricyclic farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A2 (fr) * 2001-04-06 2002-10-17 Schering Corporation Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
US7585864B2 (en) 2004-12-13 2009-09-08 Schering Corporation Farnesyl protein transferase inhibitors and their use to treat cancer
CN101128202A (zh) 2004-12-14 2008-02-20 先灵公司 法呢基蛋白质转移酶抑制剂和用于治疗增殖性疾病的方法
WO2007084498A1 (fr) * 2006-01-19 2007-07-26 Schering Corporation Dérivés de pipérazine en tant qu'inhibiteurs de farnésyl transférase
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
MX382905B (es) 2014-03-19 2025-03-13 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)-3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
ZA985203B (en) 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
SK7592001A3 (en) 1998-12-18 2002-03-05 Schering Corp Tricyclic farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
TR200101755T2 (tr) 2001-09-21
CA2354779A1 (fr) 2000-06-29
NO20012961D0 (no) 2001-06-15
CO5160350A1 (es) 2002-05-30
EP1140902A1 (fr) 2001-10-10
AR021718A1 (es) 2002-07-31
PE20001342A1 (es) 2000-12-09
NZ511878A (en) 2003-10-31
AU2030700A (en) 2000-07-12
IL143408A0 (en) 2002-04-21
WO2000037459A1 (fr) 2000-06-29
CZ20011950A3 (cs) 2001-12-12
KR20010081116A (ko) 2001-08-27
SK7592001A3 (en) 2002-03-05
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
ZA200104233B (en) 2002-08-22
BR9916314A (pt) 2001-10-02
CN1334811A (zh) 2002-02-06
CN1326850C (zh) 2007-07-18
JP2002533336A (ja) 2002-10-08
PL348293A1 (en) 2002-05-20

Similar Documents

Publication Publication Date Title
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
DK1076663T3 (da) Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
ATE159012T1 (de) Arylsulfonamido-substituierte hydroxamsäure derivate
CA2354774A1 (fr) Inhibiteurs de la farnesyl proteine transferase
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
CA2318145A1 (fr) Derives d'acide sulfonylamino inhibant des metalloproteases de degradation de matrice
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NO20012961L (no) Trisykliske farnesylproteintransferase-inhibitorer
KR20050042829A (ko) 세포 유착 저해제
AU7949791A (en) Diaminotrifluoromethylpyridine derivatives, process for their production and phospholipase a2 inhibitor containing them
BR0210746A (pt) Derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina tendo atividade antiviral
MXPA04004802A (es) Derivados del 1,2,4-triazol que contienen un grupo sulfamato como inhibidores de aromatasa.
ATE209201T1 (de) Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
EP0713877A4 (fr) Derives de qinghaosu utilises pour lutter contre le sida
NO991235L (no) Forbindelser anvendelige for inhibering av farnesylproteintransferase
DK1387841T3 (da) Hidtil ukendt azol- eller triazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som fungicider
ATE312086T1 (de) Phenoxazinanaloge zur behandlung von amyloidose
WO2000034247A3 (fr) Procede de production de derives de pyrazolylbenzoyl et nouveaux derives de pyrazolylbenzoyl
ATE248831T1 (de) Benzo(5,6)cyclohepta(1,2b)pyridine derivate anwendbar als farnesyl protein transferase inhibitoren
NO962809L (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ECSP993273A (es) Inhibidores de transferasa de proteina farnesilo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application